The Gargoyle Investment Advisor L.L.C. decides to keep it stake in Gilead Sciences Inc. (GILD) to the level of $1,207,000

The Gargoyle Investment Advisor L.L.C. decides to keep it stake in Gilead Sciences Inc. (GILD) to the level of $1,207,000

Gargoyle Investment Advisor L.L.C. held its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,480 shares of the biopharmaceutical company’s stock at the end of the second quarter. Gargoyle Investment Advisor L.L.C.’s holdings in Gilead Sciences were worth $1,207,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in GILD. Joel Isaacson & Co. LLC raised its position in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares during the last quarter. Jolley Asset Management LLC raised its stake in shares of Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 682 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 301 shares in the last quarter. North Star Investment Management Corp. raised its stake in shares of Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 700 shares in the last quarter. Finally, Peoples Financial Services CORP. raised its stake in shares of Gilead Sciences by 30.4% in the second quarter. Peoples Financial Services CORP. now owns 2,575 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 600 shares in the last quarter. Institutional investors own 77.93% of the company’s stock.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.42% during midday trading on Friday, reaching $72.75. 7,359,055 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $77.93 and its 200 day moving average price is $84.45. The stock has a market capitalization of $96.01 billion, a P/E ratio of 6.38 and a beta of 1.10. Gilead Sciences Inc. has a 1-year low of $72.21 and a 1-year high of $111.11.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. Gilead Sciences’s revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.15 EPS. On average, equities analysts predict that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were issued a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.58%. Gilead Sciences’s payout ratio is 16.56%.

GILD has been the subject of a number of research reports. Leerink Swann reiterated a “buy” rating and set a $120.00 target price on shares of Gilead Sciences in a research note on Tuesday, June 21st. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $95.02 target price for the company. in a research note on Wednesday, July 6th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a research note on Monday, July 11th. Credit Suisse Group AG reiterated a “buy” rating and set a $120.00 target price on shares of Gilead Sciences in a research note on Wednesday, June 29th. Finally, RBC Capital Markets set a $105.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, August 11th. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $104.71.

In other news, Director Kevin E. Lofton sold 3,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $79.81, for a total transaction of $159,620.00. Following the completion of the sale, the executive vice president now directly owns 64,122 shares in the company, valued at $5,117,576.82. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment